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ABSTRACT Vancomycin-resistant Enterococcus faecium bloodstream infections (VREF-
BSI) cause significant mortality, highlighting the need to optimize their treatment.
We compared the effectiveness and safety of daptomycin (DAP) and linezolid (LZD)
as continuous or sequential therapy for VREF-BSI in a national, retrospective, propen-
sity score (PS)-matched cohort study of hospitalized Veterans Affairs patients (2004
to 2014). We compared clinical outcomes and adverse events among patients
treated with continuous LZD, continuous DAP, or sequential LZD followed by DAP
(LZD-to-DAP). Secondarily, we analyzed the impact of infectious diseases (ID) consul-
tation and source of VREF-BSI. A total of 2,630 patients were included in the effec-
tiveness analysis (LZD [n  1,348], DAP [n  1,055], LZD-to-DAP [n  227]). LZD was
associated with increased 30-day mortality versus DAP (risk ratio [RR], 1.11; 95% con-
fidence interval [CI], 1.01 to 1.22; P  0.042). After PS matching, this relationship
persisted (RR, 1.13; 95% CI, 1.02 to 1.26; P  0.015). LZD-to-DAP switchers had lower
mortality than those remaining on LZD (RR, 1.29; 95% CI, 1.03 to 1.63; P  0.021),
suggesting a benefit may still be derived with sequential therapy. LZD-treated pa-
tients experienced more adverse events, including a 50% reduction in platelets
(RR, 1.07; 95% CI, 1.03 to 1.11; P  0.001). DAP was associated with lower mortality
than was LZD in patients with endocarditis (RR, 1.20; 95% CI, 1.02 to 1.41; P 
0.024); however, there was no statistically significant association between treatment
group and mortality with regard to other sources of infection. Therefore, source of
infection appears to be important in selection of patients most likely to benefit from
DAP over LZD.
KEYWORDS Enterococcus, antimicrobial resistance, bloodstream infection,
daptomycin, linezolid, transplant infectious diseases, vancomycin resistance
Vancomycin-resistant Enterococcus faecium bloodstream infections (VREF-BSI) rep-resent a significant health care-associated complication (1–4). The clinical impact of
VREF-BSI is increasing, and most E. faecium strains are now vancomycin resistant (1, 2).
As mortality associated with VREF-BSI is high, optimal treatment balancing effective-
ness and safety is critical (1, 5).
Many small retrospective studies have compared daptomycin (DAP) and linezolid
(LZD) for treatment of VREF-BSI (6–10). Two recent meta-analyses of these investiga-
tions found an apparent survival benefit associated with LZD treatment, despite the
fact that none of the individual studies included found a statistically significant differ-
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ence between the two agents in adjusted analyses (11, 12). The comparative effective-
ness of DAP and LZD for VREF-BSI was recently evaluated in a large national cohort
study of hospitalized patients in the Veterans Affairs (VA) health care system (13). In this
study, DAP treatment was associated with improved clinical and microbiologic out-
comes relative to LZD (13). While this study addressed several limitations of previous
evaluations, many clinically important questions remain unanswered (13, 14). Specifi-
cally, patients who were treated sequentially with DAP and then LZD were excluded
from previous analyses, and this may have produced biased results if a significant
portion of patients switched therapy due to clinical failure (13, 14). The impacts of
infectious diseases (ID) consultation and source of infection on outcomes in VREF-BSI
have also not been extensively evaluated (13, 14). The present study sought to expand
on findings of previous studies of VREF-BSI and address these gaps in the literature.
RESULTS
A total of 2,779 patients met study criteria (LZD, n  1,348 [48.5% of total study
patients]; DAP, n  1,055 [38.0%]; LZD-to-DAP, n  227 [8.2%]; DAP-to-LZD, n  149
[5.4%]). These individuals were treated at 99 VA medical centers across 48 states, the
District of Columbia, and Puerto Rico. Of these patients, 539/2,779 (19.4%) were
included in a previous study of hospitalized VA patients with VRE-BSI (13). The median
DAP dose was 6.15 mg/kg (total body weight; interquartile range [IQR], 5.57 to 7.07
mg/kg). All patients treated with LZD received 600 mg twice daily. The median duration
of treatment was 13 days (IQR, 7 to 18 days) for DAP, 9 days (IQR, 5 to 15 days) for LZD,
and 16 days (IQR, 11 to 27 days) for LZD-to-DAP. The median time to switching from
LZD to DAP was 6 days (IQR, 2 to 10 days).
Baseline characteristics were compared between DAP, LZD, and LZD-to-DAP treat-
ment groups, and many significant differences were noted (see Table S1 in the
supplemental material). After propensity score (PS) derivation, 853 DAP patients were
matched with 853 LZD patients and 217 LZD patients were matched to 217 LZD-to-DAP
patients (Table 1). PS matching successfully balanced these treatment groups on
baseline characteristics.
Continuous LZD versus DAP treatment. Prior to PS matching, 30-day mortality
was significantly higher among patients treated with LZD in comparison to DAP (34.6%
versus 30.7%; risk ratio [RR], 1.11; 95% confidence interval [CI], 1.01 to 1.22; P  0.042).
Continuous LZD treatment also resulted in significantly higher infection-related mor-
tality (5.3% versus 1.4%; RR, 1.04; 95% CI, 1.02 to 1.06; P  0.001), persistent VREF-BSI
(10.1% versus 6.3%; RR, 1.32; 95% CI, 1.02 to 1.71; P  0.020), hospital mortality (36.6%
versus 29.6%; RR, 1.20; 95% CI, 1.09 to 1.33; P  0.001), longer median duration of
VREF-BSI (3 days versus 2 days; P  0.001), and longer median hospital length of stay
among survivors (LOS; 26 days versus 20 days; P  0.001).
After PS matching, the relationship between LZD treatment and increased 30-day
mortality persisted (Table 2). LZD treatment was also significantly associated with
increased infection-related mortality, persistent VREF-BSI, hospital mortality, and longer
median duration of VREF-BSI and hospital LOS in the PS-matched cohort (Table 2).
Continuous LZD versus sequential LZD-to-DAP treatment. Among the 227 pa-
tients treated with sequential LZD-to-DAP, 138 (60.8%) were switched due to clinical
failure, 69 (30.4%) due to an adverse event, 9 (4.0%) due to physician preference, and
11 (4.8%) due to an unspecified reason. After PS matching, LZD treatment was
associated with increased 30-day mortality (34.6% versus 24.4%; RR, 1.29; 95% CI, 1.03
to 1.63; P  0.021) (Table 2) and lower overall survival (log-rank test, P  0.001). No
significant differences in other measured clinical outcomes were observed in this
cohort. Longer median time to switching was associated with increased 30-day mor-
tality (3 days versus 6 days; P  0.001). In a Cox regression controlling for treatment as
a time-dependent covariate, switching to DAP was associated with improved survival
compared with remaining on LZD treatment (hazard ratio, 1.21; 95% CI, 1.06 to 1.44;
P  0.001).
Britt et al. Antimicrobial Agents and Chemotherapy
May 2017 Volume 61 Issue 5 e02216-16 aac.asm.org 2
 on O







TABLE 1 Baseline characteristics among patients treated with continuous DAP, continuous LZD, or sequential DAP-to-LZD treatment for
VREF-BSI, after propensity score matchinga
Characteristic
No. (%) of patients with characteristic and P valueb for comparison
Continuous treatment (total n) Sequential treatment (total n)
DAP (853) LZD (853) P value LZD (217) LZD-to-DAP (217) P value
Age  65 yrs 412 (48.3) 420 (49.2) 0.698 101 (50.7) 102 (47.0) 0.923
Male gender 830 (97.3) 831 (97.4) 0.880 209 (96.3) 213 (98.2) 0.242
Concomitant pneumoniac 33 (3.9) 30 (3.5) 0.700 21 (9.7) 21 (9.7) 0.999
Facility complexity level
1a (most complex) 606 (71.0) 596 (69.9) 0.596 139 (64.1) 129 (59.4) 0.323
1b 162 (19.0) 148 (17.4) 0.379 53 (24.4) 47 (21.7) 0.494
1c 70 (8.2) 81 (9.5) 0.348 22 (10.1) 31 (14.3) 0.187
2 11 (1.3) 19 (2.2) 0.141 2 (0.9) 8 (3.7) 0.105
3 (least complex) 4 (0.5) 9 (1.1) 0.164 1 (0.5) 2 (0.9) 0.999
Yr of infection
2004 60 (7.0) 77 (9.0) 0.130 17 (7.8) 22 (10.1) 0.401
2005 83 (9.7) 85 (10.0) 0.871 21 (9.7) 26 (12.0) 0.440
2006 73 (8.6) 84 (9.8) 0.357 26 (12.0) 33 (15.2) 0.327
2007 95 (11.1) 107 (12.5) 0.369 29 (13.4) 25 (11.5) 0.561
2008 102 (12.0) 110 (12.9) 0.557 26 (12.0) 24 (11.1) 0.764
2009 104 (12.2) 104 (12.2) 0.999 23 (10.6) 23 (10.6) 0.999
2010 85 (10.0) 77 (9.0) 0.509 26 (12.0) 15 (6.9) 0.071
2011 89 (10.4) 69 (8.1) 0.095 16 (7.3) 14 (6.5) 0.658
2012 71 (8.3) 55 (6.4) 0.139 19 (8.8) 22 (10.1) 0.622
2013 62 (7.3) 52 (6.1) 0.332 5 (2.3) 4 (1.8) 0.522
2014 29 (3.4) 33 (3.9) 0.605 9 (4.1) 9 (4.1) 0.999
Infectious diseases consultd 424 (49.7) 421 (49.4) 0.884 114 (52.5) 124 (57.1) 0.335
Source of VREF-BSI
Genitourinary only 99 (11.6) 96 (11.3) 0.819 27 (12.4) 29 (13.4) 0.775
Abdominal/gastrointestinal only 36 (4.2) 42 (4.9) 0.487 11 (5.1) 7 (3.2) 0.064
Line-associated only 89 (10.4) 107 (12.5) 0.172 12 (5.5) 12 (5.5) 0.999
Endocarditis/cardiac device only 57 (6.7) 67 (7.9) 0.351 30 (13.8) 29 (13.4) 0.889
Wound/bone only 25 (2.9) 31 (3.6) 0.415 12 (5.5) 8 (3.7) 0.684
Multiple sources 127 (14.9) 113 (13.2) 0.330 39 (18.0) 46 (21.2) 0.397
Unknown source 420 (49.2) 397 (46.5) 0.119 86 (39.6) 86 (39.6) 0.999
Previous VRE stool colonizatione 95 (11.1) 85 (10.0) 0.431 19 (8.8) 30 (13.8) 0.095
Time to treatment (days)f [median (IQR)] 3 (2–4) 3 (2–4) 0.657 3 (2–5) 3 (2–4) 0.489
Concomitant -lactam treatmentg 662 (77.6) 653 (76.6) 0.604 193 (88.9) 185 (85.3) 0.252
Concomitant aminoglycoside treatmenth 90 (10.6) 94 (11.0) 0.755 38 (17.5) 33 (15.2) 0.516
Intensive care unit admission 271 (31.8) 272 (31.9) 0.959 72 (33.2) 73 (33.6) 0.919
Malignancy
Any malignancy 301 (35.3) 292 (34.3) 0.684 124 (57.1) 124 (57.1) 0.999
Solid tumor 194 (22.7) 183 (21.5) 0.521 91 (41.9) 91 (41.9) 0.999
Hematologic 186 (21.8) 164 (19.2) 0.187 40 (18.4) 51 (23.5) 0.195
Solid organ transplant recipient 31 (3.6) 26 (3.0) 0.501 13 (6.0) 4 (1.8) 0.065
Kidney 7 (0.8) 8 (0.9) 0.795 5 (2.3) 1 (0.5) 0.215
Liver 22 (2.6) 17 (2.0) 0.418 8 (3.7) 3 (1.4) 0.221
Lung 2 (0.2) 0 (0.0) 0.500 1 (0.5) 0 (0.0) 0.999
Heart 2 (0.2) 1 (0.1) 0.999 0 (0.0) 0 (0.0)
Comorbid conditions
Charlson comorbidity index [median (IQR)] 7 (4–9) 7 (4–9) 0.672 6 (4–8) 7 (4–9) 0.121
Moderate to severe renal disease 444 (52.1) 440 (51.6) 0.846 117 (53.9) 112 (51.6) 0.631
Severe liver disease 79 (9.3) 83 (9.7) 0.741 26 (12.0) 20 (9.2) 0.349
Metastatic solid tumor 104 (12.2) 110 (12.9) 0.661 39 (18.0) 39 (18.0) 0.999
HIV infection 25 (2.9) 29 (3.4) 0.580 7 (3.2) 7 (3.2) 0.999
(Continued on following page)
Sequential Therapy for VREF-BSI Antimicrobial Agents and Chemotherapy
May 2017 Volume 61 Issue 5 e02216-16 aac.asm.org 3
 on O







Infection source. A comparison of 30-day mortality by treatment with LZD or DAP
stratified by source of infection is displayed in Fig. 1. Among patients meeting criteria
for definite infective endocarditis who were treated with continuous therapy, LZD was
significantly associated with increased 30-day mortality compared to DAP (30.9% [n 
30/97] versus 17.2% [n  17/99]; RR, 1.20; 95% CI, 1.02 to 1.41; P  0.024). This mortality
benefit was sustained at 60 days (47.4% [n  46/97] versus 31.3% [n  31/99]; RR, 1.31;
95% CI, 1.04 to 1.65; P  0.021) among patients with VREF endocarditis. There was no
statistically significant association between treatment and 30-day mortality with regard
to other sources of VREF-BSI. While not statistically significant, DAP appeared to be
associated with proportionally lower mortality than LZD for patients with multiple
sources or a wound/bone source of VREF-BSI. There was no difference in 30-day
mortality between LZD and DAP among those with a nonendocarditis source of
infection (34.9% versus 32.1%; RR, 1.04; 95% CI, 0.98 to 1.11; P  0.165).
Infectious diseases consultation. In the full cohort of patients treated with con-
tinuous or sequential LZD or DAP (n  2,779), ID consultation was associated with
decreased 30-day mortality (27.7% [n  370/1,335] versus 38.0% [n  549/1,444]; RR,
0.86; 95% CI, 0.82 to 0.90; P  0.001). The effect of ID consultation was further analyzed
within stratum for each treatment group. ID consultation was associated with de-
TABLE 1 (Continued)
Characteristic
No. (%) of patients with characteristic and P valueb for comparison
Continuous treatment (total n) Sequential treatment (total n)
DAP (853) LZD (853) P value LZD (217) LZD-to-DAP (217) P value
Neutropenia 90 (10.6) 82 (9.6) 0.520 23 (10.6) 25 (11.5) 0.760
Thrombocytopenia 231 (27.1) 199 (23.3) 0.074 60 (27.6) 46 (21.1) 0.118
APACHE II scorei [median (IQR)] 14 (10–17) 13 (10–18) 0.790 13 (9–17) 14 (11–18) 0.320
aPropensity scores were derived from the following covariates: age  65 years, concomitant pneumonia, facility complexity level, year of infection, infectious diseases
consultation, source of VREF-BSI, previous VRE colonization, concomitant -lactam treatment, intensive care unit admission, malignancy, solid organ transplant,
Charlson comorbidity index, moderate or severe renal disease, severe liver disease, neutropenia, and thrombocytopenia.
bCategorical variables compared with the chi-square or Fisher’s exact test; continuous variables were compared with the Mann-Whitney U test.
cWithin 72 h of index culture.
dWithin 48 h of treatment initiation.
ePositive VREF stool screening within preceding 90 days; negative culture data not available.
fTime from index VREF blood culture to first dose of daptomycin or linezolid.
gAt least one dose of the following: ampicillin, ampicillin-sulbactam, ticarcillin-clavulanate, aztreonam, cefazolin, cefotaxime, ceftazidime, ceftriaxone, cefepime,
ertapenem, meropenem, doripenem, imipenem-cilastatin, or piperacillin-tazobactam.
hAt least one dose of the following: amikacin, gentamicin, or tobramycin.
iAPACHE II, Acute Physiology and Chronic Health Evaluation II study.
TABLE 2 Comparison of clinical outcomes among patients treated continuously with DAP versus LZD and LZD versus LZD-to-DAP for
VREF-BSI, after propensity score matchinga
Outcome

















30-day all-cause mortality [n (%)] 251 (29.4) 298 (34.9) 1.13 (1.02–1.26) 0.015 75 (34.6) 53 (24.4) 1.29 (1.03–1.63) 0.021
Infection-related mortalityb [n (%)] 12 (1.4) 46 (5.4) 1.47 (1.19–2.09) 0.001 16 (7.4) 15 (6.9) 1.04 (0.71–1.51) 0.852
Hospital mortality [n (%)] 250 (29.3) 305 (35.8) 1.16 (1.05–1.39) 0.004 88 (40.6) 71 (32.7) 1.19 (0.97–1.46) 0.090
Persistent VREF-BSIc,d [n (%)] 37 (6.4) 54 (10.0) 1.30 (1.02–1.67) 0.027 19 (10.3) 8 (5.4) 1.54 (0.85–2.80) 0.107
Duration of VREF-BSI (days)d,e
[median (IQR)]
2 (1–3) 3 (2–4) 0.001 2 (1–5) 2 (1–4) 0.248
Hospital length of stay (days)
[median (IQR)]
21 (12–43) 25 (14–47) 0.001 24 (14–51) 22 (10–45) 0.165
aCategorical variables were compared by using a chi-square or Fisher’s exact test. Continuous variables were compared by using the Mann-Whitney U test. Propensity
scores were derived from the following covariates: age  65 years, concomitant pneumonia, facility complexity level, infectious diseases consultation, source of VREF-
BSI, previous VRE colonization, concomitant -lactam treatment, intensive care unit admission, malignancy, solid organ transplant, Charlson comorbidity index,
moderate to severe renal disease, severe liver disease, neutropenia, or thrombocytopenia.
bDeath during treatment with DAP or LZD without microbiological clearance from bloodstream.
cLack of microbiological clearance after 7 days.
dComparison among those with at least 1 follow-up blood culture while on treatment (LZD [n  539], DAP [n  578]).
eComparison among those with at least 1 follow-up blood culture while on treatment (LZD [n  184], LZD-to-DAP [n  147]).
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creased 30-day mortality among DAP patients (26.1% [n  149/571] versus 36.2% [n 
175/484]; RR, 0.86; 95% CI, 0.80 to 0.94; P  0.001) and LZD patients (28.8% [n 
158/548] versus 38.6% [n  309/800]; RR, 0.86; 95% CI, 0.80 to 0.93; P  0.001). Among
LZD-to-DAP patients, a similar reduction in 30-day mortality was observed in cases with
ID consultation (29.8% [n  36/121] versus 39.6% [n  42/106]; RR, 0.86; 95% CI, 0.71
to 1.04; P  0.118).
Adverse events. Overall, elevated creatine phosphokinase (CPK) was rare and
occurred in only 3.0% of evaluable patients (n  37/1,249). There were, however,
statistically significant differences in CPK elevation between treatment groups (P 
0.001) (Table 3). No significant difference in CPK elevation was observed between
patients treated with DAP versus those treated with LZD (P  0.161). Patients who
received DAP at any time were no more likely to experience elevated CPK than those
with only LZD exposure (2.9% [n  29/1,000] versus 3.2% [n  8/249]; P  0.687).
However, patients who switched from DAP to LZD had significantly more frequent CPK
elevation than all other patients (P  0.001).
Thrombocytopenia occurred in 12.3% (n  330/2,687), and there was a 50% drop
in platelet count in 19.9% (n  506/2,547) of evaluable patients. These frequencies
varied significantly between treatment groups (P  0.001) (Table 3). As shown, throm-
bocytopenia was relatively rare among patients treated continuously with LZD and was
most frequent among patients who were switched from LZD to DAP. Patients with LZD
exposure at any time were no more likely to develop thrombocytopenia than those
who only received DAP (13.8% [n  229/1,664] versus 9.9% [n  101/1,023]; P  0.411).
However, patients with any LZD exposure were significantly more likely to experience
FIG 1 Comparison of 30-day mortality by treatment with LZD or DAP, stratified by source of infection.
TABLE 3 Frequency of adverse events, by antimicrobial treatment group for VREF-BSI
Adverse event
Continuous treatment Sequential treatment
Overall
P valueaDAP only LZD only P value LZD to DAP DAP to LZD P value
Thrombocytopeniab 101/1,023 (9.9) 145/1,301 (11.1) 0.478 60/219 (27.4) 24/144 (16.7) 0.130 0.001
Platelets decreased 50%
from baselinec
166/978 (17.0) 217/1,225 (17.7) 0.648 87/203 (42.9) 36/141 (25.5) 0.011 0.001
CPK elevationd 13/747 (1.7) 8/249 (3.2) 0.161 4/150 (2.7) 12/103 (11.7) 0.006 0.001
aAdverse events were compared for all groups by using the chi-square test.
bThrombocytopenia was defined as a platelet count of 50,000/l.
cOur analysis included only those with 1 follow-up platelet count.
dCPK elevation was defined based on a patient having one of two conditions: (i) among patients with normal baseline CPK, an elevated CPK value 3 times the
upper limit of normal based on two sequential measurements during the period from day 4 of treatment to 3 days after therapy, with one of these measures
being 5 times the upper limit of normal; or (ii) among patients with elevated baseline CPK, an elevated CPK value 5 times the upper limit of normal based on
two sequential measurements during the period from day 4 of treatment to 3 days after therapy.
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a 50% drop in platelet count than were those with only DAP exposure (21.7% [n 
340/1,569] versus 17.0% [n  166/978]; P  0.001).
DISCUSSION
In a national PS-matched cohort study, DAP was associated with lower 30-day
mortality, infection-related mortality, hospital mortality, persistent VREF-BSI, median
duration of VREF-BSI, and hospital LOS compared to LZD. Additionally, switching from
LZD to DAP was associated with improved survival compared to continuing LZD; which
is a novel and clinically important finding.
The mortality rates we observed were similar to those of previous studies comparing
DAP and LZD for VREF-BSI (7–13, 15). Infection-related mortality was low relative to the
overall mortality observed in the present study. This may reflect the limited virulence
of E. faecium in the context of a patient population with a high comorbidity burden and
baseline mortality risk (16, 17). As no consensus definition for infection-related mortality
or persistent infection exists, the definitions used were arbitrary and our data may
represent conservative estimates.
The finding of improved 30-day mortality associated with DAP versus LZD was
previously described in a study of VA patients (13). The mechanism for the more
favorable clinical outcomes we observed with DAP treatment remains to be elucidated,
but it may be related to the bactericidal activity of DAP against VREF in comparison to
the bacteriostatic agent LZD (18). One other explanation is the potential synergy with
concomitant -lactam or aminoglycoside treatment (19–21). However, daptomycin
combination therapy failed to improve outcomes in a previous study of VA patients
with VREF-BSI (13). Cases of VREF-BSI refractory to monotherapy or with an associated
elevated DAP MIC may represent unique populations that could benefit from concom-
itant -lactam or aminoglycoside therapy; we were unable to characterize this (22).
Patients receiving combination therapy likely have a higher baseline risk of mortality
and complex treatment courses; thus, the comparative effectiveness of daptomycin
monotherapy versus combination therapy in VREF-BSI warrants further investigation.
The benefits of sequential therapy have been well-described in the literature for
other Gram-positive BSIs, but they had not been explored in VREF-BSI prior to the
present study. Notably, the majority of LZD-to-DAP patients were switched relatively
early during the course of infection, and a shorter time to switching was associated with
improved mortality. Additionally, approximately 40% of these therapeutic switches
were due to a reason other than clinical failure, and many of these patients may have
had a favorable outcome if LZD had been continued. Inherent to any study of
sequential treatment is the possibility of survivor bias, in which patients who live longer
have a prolonged opportunity to switch therapy. However, when treatment was modeled
as a time-dependent covariate in a Cox regression to account for this effect, the relationship
between switching from LZD to DAP and improved survival persisted. These results suggest
that switching treatment from LZD to DAP, particularly early in the course of infection, may
lead to more favorable outcomes than would continuation of LZD.
Regarding infection source, DAP was associated with improved 30-day mortality
among patients with VREF endocarditis. Recently published clinical practice guidelines
recommend either high-dose DAP or LZD first-line therapy for these infections (23). The
results of the present study suggest that DAP treatment may be associated with
improved mortality in VREF endocarditis, a relationship which should be further eval-
uated in a study properly adjusting for DAP dose and other potential confounders, such
as surgical intervention. Importantly, DAP was not associated with improved outcomes
in any other subgroup of infection source. This suggests that source of VREF-BSI may
play an important role in outcomes and could be useful in guiding treatment selection.
It should be noted, however, that daptomycin had a numerically lower risk of mortality
for all distinct sources of infections, except for abdominal/gastrointestinal infections.
These subgroups also featured a limited number of patients and were likely under-
powered. Further evaluation of the relationship between infection source and out-
comes in VREF-BSI is warranted.
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To our knowledge, the present study is also the first to demonstrate the impact of
ID consultation on clinical outcomes among patients with VREF-BSI, regardless of
treatment. This finding was in an unadjusted secondary analysis and should be hy-
pothesis generating, requiring confirmation in other data sets with consideration of
potential confounding factors. However, ID specialist consultation has previously been
associated with improved clinical outcomes in other Gram-positive BSIs, perhaps due to
more diligent and aggressive source identification and control (24, 25). In a recent
analysis of hospitalized VA patients with VRE-BSI treated with daptomycin, ID specialist
consultation was also independently associated with improved survival (26). We believe
future analyses of VREF-BSI should consider the potential influence of ID consultation
on clinical outcomes.
This investigation included a safety analysis of DAP and LZD used to treat VREF-BSI.
Despite a large sample size, DAP-exposed patients were no more likely to experience
elevated CPK than LZD-exposed patients. In contrast, LZD-exposed patients were
significantly more likely to experience a 50% decrease in platelet count from baseline,
a threshold frequently used to indicate drug-induced thrombocytopenia (27). Addition-
ally, an adverse event to LZD was the primary reason for switching in nearly one-third
of cases with sequential therapy.
The present study is not without limitations. While the use of PS matching balanced
the treatment groups with regard to baseline characteristics and enhanced internal
validity, we cannot exclude the potential influence of unmeasured or residual con-
founders (28, 29). The large-scale investigation of national clinical databases improved
the external validity of this study; however, we were unable to collect potentially
important data which were not available from these data sources at the time of the
study, including time-to-culture positivity, source control, and perceived source of
infection as documented by a treating physician. We attempted to overcome the latter
by identification of microbiologically confirmed VREF infection from other sites; how-
ever, no such data existed for nearly half of the included patients. The screening
methodology used to identify cases of VREF endocarditis would also have been unable
to capture those without an ICD-9 code. Additionally, VRE colonization status was not
known for all patients and the timing and frequency of follow-up blood cultures was
left to physician discretion. The present study featured a primarily male, elderly cohort
with a relatively small number of solid organ and hematopoietic stem cell transplant
recipients; therefore, these results should be interpreted within the context of the
population studied.
In conclusion, DAP was associated with improved clinical outcomes and fewer
adverse events than LZD in the treatment of VREF-BSI. Improved outcomes associated
with DAP use were most apparent in patients with VREF endocarditis, and there was no
statistically significant advantage of DAP therapy in patients with other sources of
infection. Therefore, consideration of infection source appears to be important in the
selection of VREF-BSI patients most likely to benefit from DAP therapy over LZD. We
recommend consideration of early switching to DAP among those treated initially with
LZD for VREF-BSI, as delays in switching were associated with poorer survival. Finally, ID
specialist consultation was associated with decreased mortality irrespective of treat-
ment modality and should be considered where possible for patients with VREF-BSI.
MATERIALS AND METHODS
Study population and data sources. We conducted a national retrospective cohort study of
hospitalized patients admitted to any VA medical center (VAMC) from 2004 to 2014. All adult patients
with 1 blood culture positive for vancomycin-resistant E. faecium were included. Exclusion criteria
included the following: (i) total duration of treatment with DAP, LZD, or sequential therapy of 48 h; (ii)
treatment with another active anti-VRE agent; (iii) VREF-BSI caused by a microbiologically confirmed
DAP-nonsusceptible or LZD-resistant isolate. For the comparative effectiveness analyses, patients were
classified into three treatment groups: (i) continuous DAP; (ii) continuous LZD; (iii) sequential LZD to DAP
(LZD-to-DAP). Two comparisons were made: (i) continuous DAP versus continuous LZD; (ii) continuous
LZD versus LZD-to-DAP (to assess the effects of sequential therapy). Patients treated with sequential DAP
to LZD (DAP-to-LZD) were included in the adverse events analysis only, as we hypothesized DAP would
be associated with more favorable outcomes based on previous research (13). This was a follow-up
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analysis to a previously published study, featuring an expanded cohort due to upgrades to the data
sources used and less-stringent exclusion criteria, to include sequential therapy and additional patients
(13). This study was approved by the Kansas City VAMC institutional review board.
Data collection and definitions. Clinical and administrative data were abstracted from national
databases comprised of records from all VAMCs to identify patients. Data collected included patient
demographics, laboratory and microbiological data (positive and negative cultures), echocardiography
reports, vital signs, antimicrobial treatment data, comorbidities, admissions records (bed type, length of
stay), ID specialist consultation within 48 h, stool VRE colonization, and date of death. Potential cases
of VREF endocarditis were initially identified by ICD-9 codes. These cases were further assessed by
retrospective review of the electronic medical record, and definite infective endocarditis cases were
identified by the modified Duke criteria (23, 30). Cases of line-associated VREF-BSI were identified based
on the presence of additional positive catheter tip cultures. All other sources of VREF-BSI were deter-
mined by microbiologic culture confirmation from another site growing VREF, drawn within 72 h of index
blood culture, when available. For patients who were treated with sequential therapy, retrospective
review of the electronic medical record was also conducted to determine the reason for switching.
Susceptibilities to antimicrobial agents were determined during routine clinical care per institution-
specific procedures, and quantitative MIC data were not available.
Clinical outcomes. The primary clinical outcome was 30-day all-cause mortality, defined from the
time of index VREF-positive blood culture. Secondary outcomes included infection-related mortality
(death during treatment with DAP or LZD for VREF-BSI without microbiologic clearance), hospital
mortality (mortality while hospitalized for VREF-BSI), duration of VREF-BSI (time from index VRE-positive
blood culture until the first negative blood culture), persistent VREF-BSI (lack of microbiologic clearance
after 7 days treatment with DAP or LZD), and hospital LOS (time from index VREF-positive blood culture
until discharge, excluding patients who died during hospitalization).
Adverse events. We evaluated the following adverse events: (i) thrombocytopenia (platelets 
50,000/l); (ii) decrease in platelet count of 50% during treatment; (iii) CPK elevation, according to
previously defined criteria (27, 31, 32). Patients with baseline thrombocytopenia were excluded from
analyses of the effect of treatment on platelet count.
Statistical analysis. Baseline patient characteristics were compared by 2 test or Fisher’s exact test
for categorical data and Student’s t test or Mann-Whitney U test for continuous data. To address potential
confounding by indication, a series of PS-matched analyses were conducted. The first analysis included
patients who were treated with DAP versus those treated with LZD, and the second included patients
treated with LZD versus those treated with LZD and then switched to DAP. For these analyses, PS were
derived from unconditional logistic regression, controlling for variables which were associated with the
primary outcome or treatment group (P  0.2) at baseline. PS matches were performed 1:1 with
replacement using a greedy nearest-neighbor algorithm (caliper width, 0.2). The effect of sequential
therapy on survival was assessed in the PS-matched cohort using the Kaplan-Meier method and log-rank
test and in a Cox regression with treatment group status modeled as a time-dependent covariate to
account for potential survival bias. Reason for switching therapy was categorized into the following
groups: (i) clinical failure (persistent leukocytosis [white blood cell count of 12,000/l], persistent fever
[body temperature of 38°C], persistent BSI [lack of microbiologic clearance prior to switching treat-
ment], or perceived clinical failure as documented by a treating physician); (ii) adverse event (develop-
ment of thrombocytopenia, elevated CPK, or as documented by a treating physician); (iii) physician
preference; (iv) unspecified (no reason for switching could be identified). The associations between
treatment group and adverse events were compared by partitioned 2 analysis. Statistical analyses were
performed using SAS software (version 9.3; SAS Institute, Cary, NC) with a two-sided P value of 0.05
considered statistically significant for all tests.
Secondary analyses. The comparative effectiveness of DAP and LZD was further analyzed after
stratification by source of VREF-BSI and ID specialist consultation. An a priori assumption was made that
ID specialist consultation could serve as a confounding or modifying variable. To address this, stratified
analyses were performed to determine if the relationship between treatment group and 30-day mortality
was modified by ID specialist consultation, prior to PS matching (33). Because this variable was
considered a potential confounder, it was also included in the PS-matching algorithm.
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